Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 5/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 2/20 | 0.32 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | CTSC | P53634 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19362764 | 0.81 | PKM (0.39) | PKMKMT2AMEN1ALDH1A1HPGD | |
| SCHEMBL16362080 | 0.79 | HSD17B10 (0.35) | PKMKMT2AMEN1ALDH1A1HPGD | |
| SCHEMBL30445159 | 0.79 | HSD17B10 (0.35) | PKMKMT2AMEN1ALDH1A1HPGD | |
| SCHEMBL30538040 | 0.79 | AHR (0.37) | PKMKMT2AMEN1ALDH1A1HPGD | |
| SCHEMBL16932343 | 0.79 | AHR (0.37) | PKMKMT2AMEN1ALDH1A1HPGD | |
| SCHEMBL19360279 | 0.76 | PPARG (0.39) | PKMKMT2AMEN1ALDH1A1HPGD | |
| SCHEMBL20172646 | 0.73 | CTSC (0.41) | PKMKMT2AALDH1A1TSHRCTSC | |
| SCHEMBL10187968 | 0.71 | ACACB (0.39) | PKMKMT2AMEN1ALDH1A1HPGD | |
| SCHEMBL14867215 | 0.70 | ASAH1 (0.42) | PKMKMT2AMEN1ALDH1A1HPGD | |
| SCHEMBL19592149 | 0.69 | CTSC (0.45) | PKMALDH1A1POLBTSHRCTSC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170267667-A1 | ALKENYLDIARYLMETHANES AS NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS FOR ANTI-HIV-1 CHEMOTHERAPY | PURDUE RESEARCH FOUNDATION (US) | 2017-09-21 | — | — | US | disclosed |
| US-20170267667-A1 | ALKENYLDIARYLMETHANES AS NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS FOR ANTI-HIV-1 CHEMOTHERAPY | PURDUE RESEARCH FOUNDATION (US) | 2017-09-21 | — | — | US | disclosed |
| US-20080300288-A1 | Alkenyldiarylmethanes, Fused Analogs And Syntheses Thereof | PURDUE RESEARCH FOUNDATION (US) | 2008-12-04 | — | — | US | disclosed |
| US-20080300288-A1 | Alkenyldiarylmethanes, Fused Analogs And Syntheses Thereof | PURDUE RESEARCH FOUNDATION (US) | 2008-12-04 | — | — | US | disclosed |
| US-20080300288-A1 | Alkenyldiarylmethanes, Fused Analogs And Syntheses Thereof | PURDUE RESEARCH FOUNDATION (US) | 2008-12-04 | — | — | US | disclosed |
| WO-2008119028-A1 | ALKENYLDIARYLMETHANES HAVING NITROGEN-CONTAINING CARBOXYLIC ACID DERIVATIVES | CUSHMAN MARK S (US) | 2008-10-02 | — | — | WO | disclosed |
| WO-2007005531-A2 | ALKENYLDIARYLMETHANES, FUSED ANALOGS AND SYNTHESES THEREOF | PURDUE RESEARCH FOUNDATION (US) | 2007-01-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080300288-A1 | Alkenyldiarylmethanes, Fused Analogs And Syntheses Thereof | POLRMT, PNP, TYMS | PKM 755/4885KMT2A 1410/4885MEN1 4353/4885 |
| US-20170267667-A1 | ALKENYLDIARYLMETHANES AS NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS FOR ANTI-HIV-1 CHEMOTHERAPY | TYMP, SAMHD1, TYMS | PKM 3683/4885KMT2A 1153/4885MEN1 4154/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.